London, May 1, 2026, 15:19 BST
The UK’s Medicines and Healthcare products Regulatory Agency has signed off on GSK plc’s Lynavoy for adult patients with primary biliary cholangitis, giving the pharma giant another regulatory nod in liver disease—right after it passed the drug along to Alfasigma. The approval, granted to GlaxoSmithKline UK Limited, marks what interim executive director of healthcare quality and access Julian Beach described as a “new treatment option” for those with PBC. Gov
Timing’s crucial. GSK wants to reassure investors about its pipeline as it faces mounting pressure from aging drugs and the 2028 patent cliff on dolutegravir, its flagship HIV medicine. Still, shares tumbled following first-quarter numbers this week. Earnings did come in ahead of forecasts, but Verso Investment Management analyst James Eugene flagged “quality concerns” with a beat he said was flattered by one-off items. Reuters
PBC, an uncommon autoimmune condition, damages bile ducts and causes bile acids to accumulate. Lynavoy—known as linerixibat—comes as a twice-daily oral tablet, targeting the cause of cholestatic pruritus, or intense itching tied to bile flow issues.
The nod also factors into GSK’s licensing pact with Italy’s Alfasigma. Alfasigma announced on April 27 that it wrapped up the agreement, giving it exclusive global rights to develop, produce and market linerixibat, following U.S. antitrust clearance. GSK stands to collect a $300 million upfront, another $100 million once it gets U.S. approval, plus $20 million more tied to EU and UK approvals. Add in up to $270 million in sales milestones, and tiered double-digit royalties based on worldwide net sales.
Everything hinges on the GLISTEN phase 3 trial for the drug. According to GSK, the study hit both its main and key secondary endpoints, showing reductions in itch and itch-related sleep problems at 24 weeks compared with placebo. Kaivan Khavandi, a top research executive at GSK, called the U.S. approval a “much needed treatment option” for patients. GSK is also billing Lynavoy as the first medicine cleared in the U.S. specifically for the itch indication in PBC. GSK
Gideon Hirschfield, who leads the autoimmune and rare liver disease program at University Health Network in Toronto and serves as lead author of the GLISTEN study, called the earlier trial results “meaningful and clinically important.” The trial included 238 patients with PBC suffering from cholestatic pruritus, putting linerixibat up against placebo. GSK
Rivals are emerging, though their focus varies. According to Reuters in March, Gilead’s Livdelzi and Ipsen’s Iqirvo are prescribed for PBC, but don’t specifically go after severe itch. Mirum Pharmaceuticals, on the other hand, is pushing forward with volixibat aimed at treating pruritus in PBC.
GSK’s headline figures remain robust. First-quarter sales landed at £7.63 billion, with core operating profit at £2.65 billion and core EPS of 46.5 pence. The company stuck to its 2026 targets: turnover up 3% to 5%, and core operating profit up 7% to 9%. Its 2031 sales projection held steady, still set above £40 billion. Chief Executive Luke Miels described the start to 2026 as “strong” and pointed to “execution and accelerating R&D” as key priorities. GSK
Investors aren’t all in. GSK shares in London slipped 1.1% to around 1,906 pence in delayed Friday trading, leaving the pharma group’s market cap close to £76.1 billion.
Ownership shifts cropped up too. According to a regulatory filing, Dodge & Cox hit a notification threshold on April 28, reporting 4.93% of GSK voting rights—these held in both ordinary shares and ADRs. The issuer got the heads-up on April 30.
Lynavoy might end up as more of a solid, supporting asset for GSK if Alfasigma can’t deliver broad adoption after approvals. Europe, China, and Canada are all still in play, but green lights from regulators don’t automatically translate to milestone payments, easy access, or big scripts. Safety concerns aren’t going away either—GSK’s own trials flagged diarrhoea and abdominal pain as the top side effects.
For Miels, a UK approval adds something to the pipeline story, though it hardly closes the book. Investors still want hard evidence that GSK will generate growth beyond HIV, maintain momentum in vaccines, and convert its late-stage pipeline into products big enough to back up the 2031 goal.
